Related Experiment Videos
Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies
G Spencer-Green1, D Alter, H G Welch
1Division of Rheumatology, Dartmouth Medical School, Hanover, New Hampshire 03756, USA.
This study reviewed 30 articles to assess how well anti-centromere and anti-Scl-70 antibodies detect systemic sclerosis (SSc). These antibodies are highly specific but not always present in SSc patients. Anti-centromere antibodies appear more often in limited cutaneous SSc (CREST subset), while anti-Scl-70 is more common in diffuse cutaneous SSc. Only a small number of patients have both antibodies. The study found that while these tests are reliable when positive, a negative result does not rule out SSc. Clinicians should use antibody testing alongside clinical features for diagnosis. The findings emphasize that antibody results should not be the sole basis for diagnosis.
Area of Science:
- Autoimmune disease diagnostics
- Rheumatology clinical testing
- Systemic sclerosis antibody profiling
Background:
Prior research has shown that systemic sclerosis (SSc) involves distinct autoantibody profiles. It was already known that anti-centromere (ACA) and anti-Scl-70 antibodies are commonly associated with SSc. However, no prior work had resolved the exact diagnostic sensitivity and specificity of these antibodies in SSc. This gap motivated a comprehensive review of available literature to clarify their utility. Researchers sought to address uncertainty surrounding how often these antibodies appear in SSc patients versus controls. They also aimed to determine if these antibodies could reliably distinguish SSc subtypes. The absence of a clear synthesis of diagnostic performance data in the literature left clinicians without definitive guidance. This review aimed to consolidate findings from multiple studies to provide clearer insights.
Purpose Of The Study:
The aim of this study was to evaluate the diagnostic accuracy of anti-centromere and anti-Scl-70 antibodies in systemic sclerosis. Researchers focused on determining how often these antibodies appear in SSc patients versus non-SSc controls. They also wanted to assess if these antibodies could help differentiate between SSc subtypes. The motivation stemmed from the need to clarify their role in clinical decision-making. Prior studies had reported variable results, which created confusion among clinicians. The authors sought to synthesize data from multiple sources to provide a clearer picture. They aimed to calculate summary sensitivity and specificity rates for each antibody. This would help establish their diagnostic value and limitations in clinical practice.
Main Methods:
The study involved a structured MEDLINE search of English-language articles published from 1966 to 1994. Researchers identified articles measuring ACA or anti-Scl-70 antibodies in both SSc patients and non-SSc controls. They applied a diagnostic testing scale to assess study quality and relevance. Each study's sensitivity and specificity were converted into 2x2 contingency tables. Summary rates were calculated by combining data across eligible studies. The authors used the original study authors' clinical criteria as the gold standard for diagnosis. They analyzed 30 articles that met inclusion criteria for final results. This approach allowed them to estimate overall diagnostic performance and variability across studies.
Main Results:
Anti-centromere antibodies were found in 441 of 1,379 SSc patients, yielding a sensitivity of 32%. This increased to 57% in patients with limited cutaneous SSc (CREST subset). Anti-Scl-70 antibodies were detected in 366 of 1,074 SSc patients, with a sensitivity of 34%. Sensitivity rose to 40% in diffuse cutaneous SSc patients. In 670 patients tested for both antibodies, 58% had at least one positive result. Only three patients had both ACA and anti-Scl-70 antibodies present. Specificity was high, with ACA found in 5% of other connective tissue disease patients and 2% for anti-Scl-70. Disease-free controls had less than 1% positivity for either antibody.
Conclusions:
The authors concluded that ACA and anti-Scl-70 antibodies are highly specific for SSc. They noted that these antibodies perform better as discriminators of clinical subsets once SSc is suspected. A positive test result can be trusted as specific, but a negative result does not rule out SSc. The authors emphasized that 40% of SSc patients may lack both antibodies. They proposed that antibody testing should follow clinical evaluation in SSc diagnosis. The findings suggest that these antibodies are useful but not definitive markers. They highlight the need for clinicians to interpret antibody results within the broader clinical context. These conclusions align with the observed data and do not introduce new hypotheses.
Frequently Asked Questions
Anti-centromere antibodies have a sensitivity of 32% in SSc patients, rising to 57% in limited cutaneous (CREST) SSc. Anti-Scl-70 antibodies have a 34% sensitivity overall and 40% in diffuse cutaneous SSc.
Anti-centromere antibodies are more common in limited cutaneous SSc (57%) than in general SSc (32%). Anti-Scl-70 antibodies are more frequent in diffuse cutaneous SSc (40%) than in general SSc (34%).
Only three patients among 670 tested had both antibodies present. This suggests that these antibodies typically appear in mutually exclusive subtypes of SSc.
Anti-centromere antibodies are present in 5% of other connective tissue disease patients and 2% for anti-Scl-70. Disease-free controls have less than 1% positivity for either antibody.
No, a negative result does not exclude SSc. Up to 40% of patients may lack both antibodies, so clinical evaluation remains essential.
The authors suggest that antibody testing should be secondary to clinical evaluation when diagnosing SSc. A positive result is specific, but a negative result does not rule out the disease.